1.
Compr Ther
; 35(3-4): 199-203, 2009.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20043618
RESUMO
Erythropoietin refractory anemias represent a continuing and increasing burden on the healthcare system. The current practice of providing these patients with rHuEPO does not seem to be working. Fewer than 50% of patients respond in some studies. We demonstrate that androgens have multiple benefits in this population. They control anemia and stop transfusion dependence and improve nutritional parameters. In some patients, they also have a salutary effect on both white blood cell and platelet counts.